Ductal Carcinoma
In Situ
411
429. Haigh PI, Giuliano AE. The Coxet al. article reviewed.
Oncology
1998;12:1293–1294.
430. Cox CE, Haddad F, Bass S, et al. Lymphatic mapping in the treatment
of breast cancer.
Oncology
1998;12:1283–1292.
431. Bombonati A, Sgroi DC. The molecular pathology of breast cancer
progression.
J Pathol
2011;223:307–317.
432. Han K, Nofech-Mozes S, Narod S, et al. Expression of HER2/neu in
ductal carcinoma
in situ
is associated with local recurrence.
Clin Oncol
(R Coll Radiol)
2012;24:183–189.
433. Espina V, Liotta LA. What is the malignant nature of human ductal
carcinoma
in situ
?
Nature
2011;11:61–65.
434. Flanagan M, Love S, Hwang ES. Status of intraductal therapy for duc-
tal carcinoma
in situ
.
Curr Breast Cancer Rep
2010;2:75–82.
435. Bleicher RJ. Ductal carcinoma
in situ
.
Surg Clin North Am
2013;93:393–410.
436. Berg CD. Resolving the ductal carcinoma
in situ
treatment conun-
drum.
J Natl Cancer Inst
2013;105:680–681.
437. Ballehaninna UK, Chamberlain RS. Inclusion of tumor biology
molecular markers to improve the ductal carcinoma
in situ
ipsilat-
eral breast tumor recurrence nomogram predictability.
J Clin Oncol
2011;29:e97–e98.
438. Bleyer A, Welch HG. Effect of three decades of screening mammogra-
phy on breast-cancer incidence.
N Engl J Med
2012;367:1998–2005.
439. Baur A, Bahrs SD, Speck S, et al. Breast MRI of pure ductal carcinoma
in situ
: sensitivity of diagnosis and influence of lesion characteristics.
Eur J Radiol
2013;82:1731–1737.
421. Cheng L, Al-Kaisi NK, Gordon NH, et al. Relationship between the
size and margin status of ductal carcinoma
in situ
of the breast and
residual disease.
J Natl Cancer Inst
1997;89:1356–1360.
422. Early Breast Cancer Trialists Collaborative Group. Effects of radiother-
apy and of differences in the extent of surgery for early breast cancer on
focal recurrence and on 15-year survival.
Lancet
2005;366:2087–2106.
423. Allred DC, Bryant J, Land S, et al. Estrogen receptor expression as a pre-
dictive marker of the effectiveness of tamoxifen in the treatment of DCIS:
findings fromNSABP protocol B-24.
Breast Cancer Res Treat
2002;76:S36.
424. Liberman L, Van Zee KJ, Dershaw DD, et al. Mammographic fea-
tures of local recurrence in women who have undergone breast-
conserving therapy for ductal carcinoma in site.
AJR Am J Roentgenol
1997;168:489–493.
425. Silverstein MJ, Gierson ED, Colburn WJ, et al. Can intraductal
breast carcinoma be excised completely by local excision?
Cancer
1994;73:2985–2989.
426. Goldstein NS, Kestin L, Vicini F. Pathologic features of initial bi-
opsy specimens associated with residual intraductal carcinoma
on reexcision in patients with ductal carcinoma
in situ
of the
breast referred for breast-conserving therapy.
Am J Surg Pathol
1999;23:1340–1348.
427. Schnitt SJ, Harris JR, Smith BL. Developing a prognostic index
for ductal carcinoma
in situ
of the breast. Are we there yet?
Cancer
1996;77:2189–2192.
428. Wood WC. Should axillary dissection be performed in patients with
DCIS?
Ann Surg Oncol
1995;2:193–194.
